title: Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and Rho kinase inhibition in osteoblastic MC3T3-E1 cells.
abstract: It is well known that parathyroid hormone (PTH) possesses an anabolic effect on bone. However, the mechanisms are not fully elucidated. So far, it is unclear whether or not PTH could stimulate the expression of bone morphogenetic protein-2 (BMP-2), a strong mediator for bone formation. Growing evidence suggests that BMP-2 expression is regulated by the mevalonate pathway and Rho-associated protein kinase (ROK) activity. This study was performed to examine if PTH affects BMP-2 expression and to clarify its involvement of the mevalonate pathway. Osteoblastic MC3T3-E1 cells were treated with human PTH-(1-34) to determine BMP-2 mRNA expression levels by real-time PCR and to measure the ROK activity by the kinase assay. Incubation with 10 (-9)-10 (-8) M of hPTH-(1-34) for 6 h induced significant upregulation of BMP-2 mRNA levels in MC3T3-E1 cells. Short-term treatment of hPTH-(1-34) suppressed Rho kinase activity and mevalonate kinase mRNA levels. PTH-induced BMP-2 mRNA upregulation was selectively reversed by geranylgeranyl pyrophosphate (GGPP) pretreatment, but not by mevalonate pretreatment. These findings suggest that BMP-2 mRNA expression was upregulated by PTH in MC3T3-E1 cells mediated by mevalonate pathway suppression followed by ROK inhibition. We have now demonstrated for the first time that PTH stimulated BMP-2 mRNA expression via the mevalonate pathway and ROK in osteoblastic MC3T3-E1 cells.
authors: Shimane University Faculty of Medicine, Department of Internal Medicine 1, Enya-cho, 693-8501 Izumo, Japan.
authors: H
authors: H
authors: Takase
authors: S
authors: S
authors: Yano
authors: T
authors: T
authors: Yamaguchi
authors: I
authors: I
authors: Kanazawa
authors: K
authors: K
authors: Hayashi
authors: M
authors: M
authors: Yamamoto
authors: M
authors: M
authors: Yamauchi
authors: T
authors: T
authors: Sugimoto
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000235:genetics* / Q000378:metabolism; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051379:Mice; D008954:Models, Biological; D010006:Osteoblasts / Q000187:drug effects* / Q000201:enzymology*; D010281:Parathyroid Hormone / Q000494:pharmacology*; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D011106:Polyisoprenyl Phosphates / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects*; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors*
chemical_list: D055396:Bone Morphogenetic Protein 2; D010281:Parathyroid Hormone; D011106:Polyisoprenyl Phosphates; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D017853:Phosphotransferases (Alcohol Group Acceptor); C021796:mevalonate kinase; D054460:rho-Associated Kinases; C002963:geranylgeranyl pyrophosphate